Taiwan's Adimmune Set For Quick Production Of Rapiacta Against H7N9
This article was originally published in PharmAsia News
Executive Summary
The chairman of Taiwan-based Adimmune said that as soon as the firm receives a sample of the H7N9 avian influenza virus the subject of an outbreak in China, it would begin emergency production of its Rapiacta (peramivir).